Chana Hecht
Papers
2
Total Citations
145
H-Index
2
About
Chana Hecht is a pioneering translational researcher whose work bridges the gap between rare cancer biology and personalized medicine. Her key research areas include precision oncology, rare tumor modeling, and the use of animal avatars for drug discovery. Hecht’s major contributions center on developing personalized platforms using Drosophila (fruit flies) to identify effective therapies for patients with ultra-rare or treatment-resistant cancers. In her landmark 2019 study (107 citations), she engineered “hindgut” fly models of KRAS-mutant metastatic colorectal cancer and, through a robotics-based screen, identified the combination of trametinib plus zoledronate. Treating the patient based on this platform produced a strong partial response that remained stable for 11 months—a striking result for a difficult-to-treat malignancy. In 2021 (38 citations), she extended this approach to adenoid cystic carcinoma (ACC), a rare salivary gland cancer with limited treatment options, demonstrating the platform’s versatility. Hecht’s work is notable for its direct clinical impact: she doesn’t just discover drugs in flies—she validates them in patients, offering hope where standard therapies fail. Her innovative methodology has the potential to transform how we approach personalized therapy for rare and aggressive cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2